Final report of the SIOP-CNS-GCT II protocol for germinoma-omitting radiotherapy boost is safe in localized disease in complete remission after chemotherapy

Lymphoma

Radiotherapy may be omitted in children and adolescents with classical Hodgkin lymphoma in complete remission after frontline risk and response-adapted chemotherapy: a multicenter clinical trial (LH-GALOP 2017)

Leuk Lymphoma

Alfaro E, Schelotto M, Zamaro H, Sánchez La Rosa C, Guitter M, Romero C, Galluzzo L, Pinto N, Peruzzo L, Pages C, Nuñez F, Pennella C, Concha E, Tedesco E, Dabezies A, Castillo L, Felice MS, Zubizarreta P

doi: 10.1080/10428194.2026.2662496

Gastrointestinal Cancer

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

J Clin Oncol

Shitara K, Rha SY, Wyrwicz L, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Pietrantonio F, Lonardi S, Fang X, Guan Y, Valderrama A, Leconte P, Bhagia P, Bang YJ, KEYNOTE-585 Investigators

doi: 10.1200/JCO-25-00486

Gastrointestinal Cancer

Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial

Int J Cancer

Han W, Gao L, Wang X, Li C, Zhou Z, Deng L, Wang W, Liu W, Wang X, Chen D, Feng Q, Bi N, Zhang T, Wang J, Zhai Y, Zhao Y, Xiao Z, Jing‐Jin‐Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG)

doi: 10.1002/ijc.70176

Genitourinary Cancer

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial

J Clin Oncol

Menne Guricová K, Draulans C, Pos FJ, Kerkmeijer LGW, Monninkhof EM, Smeenk RJ, Kunze-Busch M, de Boer HCJ, van der Voort van der Zyp JRN, Haustermans K, van der Heide UA

doi: 10.1200/JCO-25-00274

Further Publications

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma

J Natl Cancer Inst

Geurts YM, Neppelenbroek SIM, Aleman BMP, Janus CPM, Krol ADG, van Spronsen DJ, Plattel WJ, Roesink JM, Verschueren KMS, Zijlstra JM, Koene HR, Nijziel MR, Schimmel EC, de Jongh E, Ong F, Te Boome LCJ, van Rijn RS, Böhmer LH, Ta BDP, Visser HPJ, Posthuma EFM, Bilgin YM, Muller K, van Kampen D, de Boer JP, So-Osman C, Vermaat JSP, de Weijer RJ, Kersten MJ, van Leeuwen FE, Appelman Y, Schaapveld M

doi: 10.1093/jnci/djag085

Gastrointestinal Cancer

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial

J Clin Oncol

Mei WJ, Wang XZ, Zhang X, Sun YM, Yang CK, Lin JZ, Wu ZG, Zhang R, Wang W, Li Y, Zhuang YZ, Lei J, Wan XB, Ren YK, Cheng Y, Li WL, Wang ZQ, Xu DB, Mo XW, Ju HX, Ye SW, Zhao JL, Zhang H, Gao YH, Zeng ZF, Xiao WW, Zhang XP, Li YF, Xie E, Feng YF, Tang JH, Wu XJ, Chen G, Li LR, Lu ZH, Wan DS, Bei JX, Pan ZZ, Yu JH, Ding PR

doi: 10.1200/JCO-25-00731

CHICAGO 2026

Genitourinary Cancer

LBA1: PROTEUS: The final analysis supports perioperative apalutamide plus ADT in patients with high-risk localized or locally advanced prostate cancer

Leukemia

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis

Haematologica

Tettero JM, Zhang MJ, Liu W, Nawas MT, Milano F, Bejanyan N, Bachanova V, Broglie L, Saber W, Gui G, Dillon LW, Walter RB, Page KM, Hourigan CS, El Chaer F

doi: 10.3324/haematol.2026.300764

Lung, Respiratory and Thoracic Cancer

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)

Eur J Cancer

Addeo A, Dietrich D, Mach N, Mark MT, Joerger M, Froesch P, Imbimbo M, König D, Fernandez E, Patzen A, Vees H, Picardi C, Früh M

doi: 10.1016/j.ejca.2025.116138

Related content

Radiotherapy may be omitted in children and adolescents with classical Hodgkin lymphoma in complete remission after frontline risk and response-adapted chemotherapy: a multicenter clinical trial (LH-GALOP 2017)

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial

LBA1: PROTEUS: The final analysis supports perioperative apalutamide plus ADT in patients with high-risk localized or locally advanced prostate cancer

Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)